Fisher Wallace Laboratories

Fisher Wallace Laboratories

Other, Brooklyn, New York, United States, 1-10 Employees

fisherwallace.com

  • facebook
  • twitter
  • instagram
  • LinkedIn

phone no Phone Number: 21********

Who is FISHER WALLACE LABORATORIES

Fisher Wallace Labs is the leading developer of wearable brain stimulation technology for the treatment of depression and other neuropsychiatric and cognitive disorders. The commercial ve...

Read More

map

industries-icon Industry: Other

SIC SIC Code: 5047 | NAICS Code: 541715 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from FISHER WALLACE LABORATORIES

Fisher Wallace Laboratories Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Fisher Wallace Laboratories

Answer: Fisher Wallace Laboratories's headquarters are located at Brooklyn, New York, United States

Answer: Fisher Wallace Laboratories's phone number is 21********

Answer: Fisher Wallace Laboratories's official website is https://fisherwallace.com

Answer: Fisher Wallace Laboratories's revenue is $5 Million to $10 Million

Answer: Fisher Wallace Laboratories's SIC: 5047

Answer: Fisher Wallace Laboratories's NAICS: 541715

Answer: Fisher Wallace Laboratories has 1-10 employees

Answer: Fisher Wallace Laboratories is in Other

Answer: Fisher Wallace Laboratories contact info: Phone number: 21******** Website: https://fisherwallace.com

Answer: Fisher Wallace Labs is the leading developer of wearable brain stimulation technology for the treatment of depression and other neuropsychiatric and cognitive disorders. The commercial version of our Version 2.0 technology, called OAK, was designed in collaboration with the teams behind Beats and Nest, and is intended to become the first superdevice for mental health that achieves smartphone scale. We completed a 255-subject, triple-blind, randomized, sham-controlled trial that demonstrated rapid effectiveness in treating depression (highly effective in the first seven days) without causing serious side effects; results will soon be published by The Journal of Clinical Psychiatry. We are now collaborating with world-class researcher partners, including Massachusetts General Hospital, to conduct a final study for FDA approval. Building towards a future in which our technology is approved to treat a universe of conditions, we recently completed a Generalized Anxiety Disorder study in collaboration with the Seattle Police Department, and are currently applying for a $5M Alzheimers research award. Under temporary FDA clearance, our Version 1.0 (proof-of-concept) technology was distributed to over 90,000 patients via 14,000 prescribers, generating $40 million in revenue, and obtained Medicaid reimbursement (MaineCare).

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access